Enhance and accelerate your early stage research with trusted and comprehensive intelligence from Thomson Reuters.

Start your free trial in just two simple steps.

Get your FREE trial

Enrich your discovery science with market leading, manually curated scientific intelligence. Systems Biology, Preclinical, Biomarkers, Chemistry, Biology, and Pharmacology - and everything in between. Covered from the perspective that matters most – yours.
Customer Feedback
Customer Feedback

Annette Bakker, Chief Scientific Officer from CTF, explains the reasons why she likes to work with Thomson Reuters. Currently using MetaCore™ to identify disease treatment options.

Live & Recorded Training

Attend one of our regularly scheduled webinar training sessions for overviews of features, tools, and content – find the schedule here

Free Pathway Maps

Search or browse through a wide range of proprietary multi-step canonical pathway maps here.

Featured News

The latest news from Life Sciences Research
The future of COPD treatment

The future of COPD treatment

Our research shows greater focus on preventative therapies

Translational Medicine

Translational Medicine

Supplement-Size Doses of Antioxidants Hasten Lung Cancer Progression

Tet Proteins Erase Epigenetic Marks

Tet Proteins Erase Epigenetic Marks

It is (reasonably) common knowledge that DNA is written in a simple four-letter code: ACTG. Too simple, actually.

Blog Highlights

Read our latest blog posts

Reimbursement Seen as ‘One of the Biggest if not the Biggest Barrier’ to Medical Device Market Entry

The Medical Device Innovation Consortium (MDIC) held a symposium in Washington to review recent advances in collaboration on regulatory science, but Bill Hawkins, the MDIC ...

Growth of Chinese Medical Device Industry Tests the Limits of its Regulators

The speed of growth of the medical device industry in China is stretching regulators to the limit. China is one of the most promising markets ...

Third Quarter – A Reality Check: The Cost of Innovative Drugs Moves into Politicos’ Crosshairs, but Biotech Will Recover

Warning signs that the biotech sector’s marathon five-year positive run had finally hit the fatigue wall were there for all to see at the end ...

Whitepapers & Publications

View our recent whitepapers and publications

Biomarkers: An indispensible addition to the drug development toolkit

In this white paper, Thomson Reuters explores the role of biomarkers as evaluative tools in improving clinical research and the ...


Latest on Twitter

Latest on Linked In